http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2274050-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f34119b232d292c72e632b62008eca90 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0534 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-37247 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-37211 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36082 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-372 |
| filingDate | 2009-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_740ecdff828bb7275d2845831f43bc2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_893d11434922996fec5b84a8a8e5d319 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f30d9ee27137a3c916232ac3493e562e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3f603d491b2a96c4df7235973b19a46 |
| publicationDate | 2011-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2274050-A2 |
| titleOfInvention | Timing therapy evaluation trials |
| abstract | A characteristic of a washout period following the delivery of therapy to a patient according to a therapy program may be determined based on a physiological parameter of the patient. A washout period includes the period of time during which a carryover effect from the therapy delivery dissipates. Monitoring a washout period may be useful for timing the delivery of therapy according to different therapy programs during a therapy evaluation period. For example, at least one physiological signal of the patient may be monitored to automatically determine when a washout period has ended, e.g., when stimulation and carryover effects of therapy delivery according to a first therapy program have substantially dissipated, in order to determine when therapy delivery according to a second therapy program can be initiated. |
| priorityDate | 2008-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 206.